Global Biopsy Needle Market By Type (Disposable, Non-Disposable) By Cancer Type (Breast, Lungs and Bronchus, Prostate, Colorectal, Pancreas, Others) By Category (Manual Biopsy Needle, Semi-Automatic Biopsy Needle, Automatic Biopsy Needle) By End-Use (Hospitals, Ambulatory Surgical Center, Other End-Uses) Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Biopsy Needle Market size is expected to be worth around USD 2.3 Billion by 2033 from USD 1.2 Billion in 2023, growing at a CAGR of 6.8% during the forecast period from 2024 to 2033.

Biopsy needles can be defined as a medical instrument used to perform a biopsy, which is a procedure to obtain a sample of cells from your body for laboratory testing. Common needle biopsy procedures include fine-needle aspiration and core needle biopsy. Needle biopsy may be used to take tissue or fluid samples from muscles, bones, and other organs, such as the liver or lungs. The biopsy needles market has witnessed significant growth driven by increasing prevalence of cancer, rising demand for minimally invasive procedures, and advancements in biopsy techniques. One major trend shaping the market is the growing preference for disposable biopsy needles, attributed to their lower risk of infection transmission and convenience in handling.

Healthcare facilities are increasingly adopting disposable biopsy needles to mitigate the risks associated with reusable ones, thereby bolstering market growth. Additionally, there’s a notable surge in the adoption of robotic-assisted biopsy procedures, enhancing precision and reducing patient discomfort during biopsies. Robotic-assisted biopsy systems offer real-time imaging guidance, enabling clinicians to accurately target tissue samples, especially in hard-to-reach areas, which contributes to improved diagnostic accuracy and patient outcomes.

Moreover, the market is witnessing innovations in biopsy needle design, focusing on features like improved visibility under imaging modalities, ergonomic handling, and compatibility with various biopsy procedures. Manufacturers are investing in R&D efforts to develop advanced biopsy needles that cater to specific clinical requirements and enhance procedural efficiency

Key Takeaways

• Market Size: Biopsy Needle Market size is expected to be worth around USD 2.3 Billion by 2033 from USD 1.2 Billion in 2023
• Market Growth: The market growing at a CAGR of 6.8% during the forecast period from 2024 to 2033.
• Type Analysis: In 2023, disposable biopsy needles dominated the market, accounting for approximately 65% of the market share.
• Cancer Type Analysis: Breast cancer is the predominant segment within the market, holding a significant 27.4% market share in 2023.
• Category Analysis: In 2023, the Manual Biopsy Needle segment dominated the market, accounting for approximately 40% of the market share.
• End-Use Analysis: In 2023, Hospitals emerged as the dominant segment, capturing approximately 70% of the market share.
• Regional Analysis: In 2023, North America dominated the Biopsy Needle Market, holding a significant 36.6% market share.

Type Analysis

Disposable Biopsy Needles are designed for single use and are widely preferred in healthcare settings due to their reduced risk of cross-contamination and infection. These needles are particularly favored in procedures that require high sterility, such as cancer biopsies. In 2023, disposable biopsy needles dominated the market, accounting for approximately 65% of the market share. This dominance is driven by the increasing emphasis on patient safety, stringent regulations regarding sterility, and the growing number of biopsy procedures globally.

On the other hand, Non-Disposable Biopsy Needles are reusable and are often chosen for their cost-effectiveness, especially in low-resource settings. However, their market share is limited compared to disposable needles due to the potential risks associated with reuse, such as infection and cross-contamination, and the additional sterilization requirements.

The growing preference for single-use medical devices is expected to further solidify the dominance of disposable biopsy needles in the market.

Cancer Type Analysis

The Biopsy Needle Market is segmented by the type of cancer targeted, including Breast, Lungs and Bronchus, Prostate, Colorectal, Pancreas, and Others. Breast cancer is the predominant segment within the market, holding a significant 27.4% market share in 2023. The high prevalence of breast cancer worldwide and the critical role of biopsies in its early detection and management contribute to this segment’s large share.

Following closely are Lungs and Bronchus Cancer and Prostate Cancer, each representing substantial segments due to their high incidence rates and the essential need for biopsy procedures in diagnosis and treatment planning. Colorectal and Pancreatic Cancers also form important parts of the market but have smaller shares compared to the leading segments. These areas are driven by the necessity for precise diagnostic procedures to improve treatment outcomes.

The Others category encompasses less common cancers, collectively forming the remainder of the market. Across all segments, disposable biopsy needles, which are favored for their safety and convenience, underscoring their widespread adoption in cancer diagnostics.

Category Analysis

The Biopsy Needle Market can be segmented based on three main categories Manual Biopsy Needle, Semi-Automatic Biopsy Needle, and Automatic Biopsy Needle. In 2023, the Manual Biopsy Needle segment dominated the market, accounting for approximately 40% of the market share. This dominance can be attributed to its widespread use in various clinical settings due to its cost-effectiveness and ease of use.

The Semi-Automatic Biopsy Needle segment follows closely, offering a balance between precision and user control, making it a popular choice in many medical procedures. Lastly, the Automatic Biopsy Needle segment, while gaining traction due to its advanced technology and higher accuracy, still lags behind the manual segment in market share. However, the automatic segment is expected to witness significant growth in the coming years due to increasing demand for minimally invasive procedures and advancements in medical technology.

End-Use Analysis

The Biopsy Needle Market can be segmented by end-use into three primary categories Hospitals, Ambulatory Surgical Centers (ASCs), and Other End-Uses. In 2023, Hospitals emerged as the dominant segment, capturing approximately 70% of the market share. This significant dominance is driven by the high volume of biopsy procedures conducted in hospital settings, which are equipped with advanced medical technologies and have a large patient base. Hospitals also benefit from skilled healthcare professionals and comprehensive facilities, making them the preferred choice for both patients and practitioners for biopsy procedures.

Ambulatory Surgical Centers represent the second-largest segment, with a growing market share due to the increasing preference for outpatient procedures that offer convenience and reduced costs. These centers are becoming more popular as they provide efficient and specialized care. The Other End-Uses segment, which includes diagnostic centers, research laboratories, and specialty clinics, accounts for a smaller share of the market but is also experiencing growth, particularly in specialized or niche applications.

Key Market Segments

By Type

• Disposable
• Non-Disposable

By Cancer Type

• Breast
• Lungs and Bronchus
• Prostate
• Colorectal
• Pancreas
• Others

By Category

• Manual Biopsy Needle
• Semi-Automatic Biopsy Needle
• Automatic Biopsy Needle

By End-Use

• Hospitals
• Ambulatory Surgical Center
• Other End-Uses

Drivers

The Biopsy Needle Market is primarily driven by the global rise in the incidence of cancer. The demand for biopsy needles is steadily increasing due to the frequent necessity of tissue sampling in the diagnosis of cancer. The market has been further stimulated by technological advancements in imaging techniques, such as MRI and ultrasound, which have improved the accuracy and ease of biopsy procedures. Furthermore, there is an increasing demand for biopsy needles due to the expanding healthcare infrastructure in developing regions and the increasing awareness of early cancer detection.

Trend

The transition to minimally invasive procedures is one of the most significant trends in the Biopsy Needle Market. The preference for fine-needle aspiration (FNA) and core needle biopsies over traditional surgical biopsies is on the rise due to their reduced patient recovery time and lower risk of complications. Furthermore, the precision and efficiency of biopsy procedures are being improved by the increasing frequency of the integration of advanced technologies such as AI-based imaging guidance and robotic-assisted biopsy systems. It is anticipated that this trend will persist as healthcare providers endeavor to enhance patient outcomes and minimize procedure-related expenses.

Restraints

The Biopsy Needle Market is confronted with specific constraints, despite its upward trajectory. The high cost of advanced biopsy needles and related imaging technologies is a significant challenge, as it can be prohibitive for patients and healthcare providers in low-income regions. Furthermore, the potential for complications, including infection or bleeding, to deter certain patients from undergoing biopsy procedures may restrict market growth.

Opportunities

Particularly in emerging markets, the Biopsy Needle Market offers numerous growth prospects. The favorable environment for market expansion is fostered by the expanding access to advanced medical technologies and the increasing healthcare expenditure in these regions. Additionally, it is anticipated that the introduction of innovative biopsy needles that provide patients with increased comfort and precision will create new opportunities for market players, thereby improving their competitive position.

Regional Analysis

In 2023, North America dominated the Biopsy Needle Market, holding a significant 36.6% market share. This leadership is driven by the region’s advanced healthcare infrastructure, high prevalence of cancer, and the strong presence of key market players. Additionally, North America’s substantial investment in medical research and technological advancements has contributed to the widespread adoption of biopsy procedures.

The region’s focus on early diagnosis and the growing demand for minimally invasive techniques further bolster its dominant position in the global market, making North America a crucial player in the biopsy needle industry.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

The global needle biopsy market’s competitive landscape offers comprehensive insights into various competitors. The information encompasses an overview of each company, financial performance, revenue generation, and market potential. Additionally, it highlights investment in research and development, new market initiatives, and the extent of global presence. The analysis also covers details about production sites and facilities, production capacities, and the strengths and weaknesses of the companies.

Moreover, it includes information on product launches, the range and diversity of products offered, and the dominance of specific applications. The data points provided specifically pertain to the companies’ activities and strategies within the global needle biopsy market.

Market Key Players

• Becton Dickinson & Company (BD)
• Medtronic plc
• Boston Scientific Corporation
• FUJIFILM Holdings Corporation
• Cardinal Health
• Hologic Inc
• Olympus Corporation
• Argon Medical Devices. Inc
• Devicor Medical Products, Inc.
• B. Braun Melsungen AG
• Cook Group Incorporated
• Stryker Corporation
• INRAD Inc.

Recent Developments

• Becton Dickinson & Company (BD): In April 2023, Becton Dickinson & Company (BD) acquired Velano Vascular, enhancing its biopsy needle portfolio. This acquisition aims to improve BD’s capabilities in vascular access technologies, aligning with the company’s strategy to expand its offerings in minimally invasive procedures and strengthen its market position in the global biopsy needle industry.
• Medtronic plc: In June 2023, Medtronic plc introduced the Bioprobe Precision biopsy needle system, designed for lung and liver biopsies. This new product offers enhanced imaging compatibility and improved targeting accuracy, aiming to streamline procedures and improve diagnostic outcomes. The launch reinforces Medtronic’s commitment to advancing biopsy technologies in the healthcare market.
• Boston Scientific Corporation: In May 2023, Boston Scientific Corporation announced its merger with Lumenis, a leading provider of energy-based medical solutions. This merger aims to integrate Lumenis’ advanced technologies into Boston Scientific’s product line, including biopsy needles, to enhance its offerings in the interventional oncology and precision medicine markets.
• Cardinal Health: In March 2023, Cardinal Health acquired a majority stake in a specialty needle manufacturer, enhancing its biopsy needle product line. This acquisition is expected to strengthen Cardinal Health’s position in the biopsy needle market by expanding its production capabilities and enabling the company to offer a broader range of specialized needle solutions.

Report Scope